Cardiol Therapeutics (CRDL) Capital Expenditures (2020 - 2026)

Cardiol Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at -$34699.3 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 317.03% year-over-year to -$34699.3; the trailing twelve-month figure through Mar 2026 stood at -$8639.4 (down 193.87% YoY), and the FY2025 full-year result was $17557.1, up 15.2% from the prior year.
• Capital Expenditures for Q1 2026 stood at -$34699.3, down from $32899.9 in the prior quarter.
• The five-year high for Capital Expenditures was $86615.0 in Q4 2023, with the low at -$34699.3 in Q1 2026.
• Historically, Capital Expenditures has averaged $5808.7 across 5 years, with a median of -$2896.7 in 2023.
• Annual changes were most pronounced in 2022 — Capital Expenditures jumped 265.19% — and 2026, when it sank 317.03%.
• Cardiol Therapeutics' Capital Expenditures stood at $74840.2 in 2022, then increased by 15.73% to $86615.0 in 2023, then slumped by 69.9% to $26071.9 in 2024, then advanced by 26.19% to $32899.9 in 2025, then plunged by 205.47% to -$34699.3 in 2026.
• The last three Capital Expenditures figures came in at -$34699.3 (Q1 2026), $32899.9 (Q4 2025), and -$2193.0 (Q3 2025), per Business Quant data.